Characterization of Flumazenil Utilization in Electroconvulsive Therapy
Michelle Yang1, Daniel McGraw2, Clint Ross2
1From The Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD and the.
The Journal of ECT
|April 15, 2025
Summary
Flumazenil administration after benzodiazepine treatment for electroconvulsive therapy (ECT) showed a statistically significant shorter seizure duration. However, flumazenil use was associated with changes in ECT electrode placement and equipment, suggesting a limited impact in this patient group.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Benzodiazepines are commonly used before electroconvulsive therapy (ECT) for sedation.
- Flumazenil is a benzodiazepine antagonist with potential to alter ECT efficacy.
- The use of flumazenil in patients receiving benzodiazepine-ก่อน ECT is not well-established.
Purpose of the Study:
- To evaluate the effectiveness of flumazenil after benzodiazepine treatment prior to ECT.
- To analyze the practice of flumazenil administration in patients undergoing ECT.
Main Methods:
- Retrospective chart review of patients receiving benzodiazepines 18 hours before ECT.
- Analysis of 847 patient encounters from July 1, 2018, to June 30, 2023.
- Primary outcome: seizure duration; Secondary outcomes: changes in electrode placement, induction agent, ECT machine, and caffeine addition.
Main Results:
- Median seizure duration was 33 seconds with flumazenil vs. 37.5 seconds without (P=0.047).
- Flumazenil use correlated with increased likelihood of changes in electrode placement (P=0.005) and ECT machine (P=0.001).
- Higher stimulus doses were associated with flumazenil administration.
Conclusions:
- Flumazenil demonstrated statistically significant differences in seizure duration and procedural modifications.
- The impact of flumazenil on benzodiazepine-treated ECT patients appears less pronounced than anticipated.
- Further research is warranted to clarify the utility of flumazenil in this specific patient population.
More Related Videos
04:51Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
9.3K
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
11.9K
Related Concept Videos
01:30Electroconvulsive Therapy
18
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
18
01:26Psychosis: Goals of Pharmacotherapy
96
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
96
01:20Antiepileptic Drugs: Potassium Channel Activators
127
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
127
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
129
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
129
01:23Antidepressant Drugs: MAOIs and Other Agents
164
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
164
01:14CNS Depressants: Barbiturates and Benzodiazepines
180
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
180